In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

• Published in: Microbial pathogenesis Vol. 145; p. 104228
• Main Authors: Andreani, Julien, Le Bideau, Marion, Duflot, Isabelle, Jardot, Priscilla, Rolland, Clara, Boxberger, Manon, Wurtz, Nathalie, Rolain, Jean-Marc, Colson, Philippe, La Scola, Bernard, Raoult, Didier
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2020; Elsevier; The Authors. Published by Elsevier Ltd
• Subjects: 2019-nCoV; animal viruses; Animals; Antiviral Agents - pharmacology; antiviral properties; Azithromycin; Azithromycin - pharmacology; Bacteriology; Betacoronavirus - drug effects; Cardiology and cardiovascular system; Cell Line; Chlorocebus aethiops; clinical trials; Coronavirus Infections - drug therapy; COVID-19; Drug Repositioning; Drug Synergism; Drug Therapy, Combination - methods; drugs; Emerging diseases; Human health and pathology; Humans; Hydroxychloroquine; Hydroxychloroquine - pharmacology; in vitro studies; Infectious diseases; Life Sciences; lungs; Microbiology and Parasitology; morbidity; mortality; pandemic; Pandemics; Parasitology; patients; Pneumonia, Viral - drug therapy; SARS-CoV-2; synergism; Vero Cells; Vero E6; Virology; Virus Replication - drug effects; viruses; COVID-19; SARS-CoV-2; Hydroxychloroquine; 2019-nCoV; Azithromycin; Vero E6

Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquin...